Top

Drugs

Published in:

01-11-2006 | Current Opinion

Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease

Potential Uses and Pitfalls

Authors: Serge Cremers, Dr Patrick Garnero

Published in: Drugs | Issue 16/2006

Abstract

Biochemical markers of bone turnover are used increasingly during the clinical development of drugs for the treatment of metabolic bone diseases such as Paget’s disease, osteoporosis and cancer that has metastasised to the bone. However, assessing the optimal value of these markers is often complicated, and such an assessment is an obvious prerequisite for rational use of the markers and, consequently, potential improvement of clinical drug development.

Biochemical markers of bone turnover are substances in the blood or urine that are produced or released during bone remodelling. They provide semiquantitative information on bone remodelling, and are often the most adequate tool to describe the pharmacodynamics of the drug. Their use has increased considerably because of dose-effect relationships that have been seen with certain drugs, but also because they have proven relationships with clinical outcomes in several metabolic bone diseases. However, there is a lack of information on the kinetics of these markers, and the immunoassays that are frequently used in their monitoring often measure a mixture of fragments rather than a single molecular entity. For drug development it should also be realised that different markers, but also different assays for the same marker, may provide different results, considerably limiting the ability to compare results.

In postmenopausal osteoporosis, relationships have been shown between several biochemical markers of bone turnover, and either fracture risk and/or the antifracture efficacy of drugs. Such relationships can be used for the development of drugs with similar mechanisms of action, but also for the development of these drugs for closely related indications, such as corticosteroid-induced osteoporosis. In both of these instances, data on effects on biochemical markers of bone turnover are usually employed in combination with information about effects on bone mineral density. However, the relationships of these parameters with clinical outcomes may be remarkably different for drugs with alternative mechanisms of action, challenging the use of the markers for the development of new drugs for the treatment of patients with osteoporosis.

At present, the pharmacological treatment of cancer that has metastasised to the bone is limited to several bisphosphonates. Recent studies have shown relationships between the normalisation of levels of biochemical markers of bone turnover and clinical outcomes, and prospective studies investigating the application of such relationships are ongoing. The markers may play an important role in the optimisation of registered bisphosphonate treatments. However, their role in the development of new drugs is still limited to dose selection, and potential relationships with clinical outcomes remain to be investigated in instances of new mechanisms of action.

Biochemical markers of bone turnover are a valuable asset for drug development, but their rational use is determined by a number of variables. Correctly manipulating these may improve clinical development of drugs for the treatment of patients with metabolic bone diseases such as osteoporosis and cancer metastatic to the bone.

The use of trade names is for product identification purposes only and does not imply endorsement.

Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338(11): 736–46PubMedCrossRef

Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 2005 Dec; 56(3): 365–78PubMedCrossRef

Papapoulos SE. Paget’s disease of bone: clinical, pathogenetic and therapeutic aspects. Ballieres Clin Endocrinol Metab 1997; 11: 117–43CrossRef

Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2004; 18(3): 1051–6

Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23(22): 4925–35PubMedCrossRef

Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complication in metastatic bone disease. Br J Cancer 2003; 89: 2031–7PubMedCrossRef

Looker AC, Bauer DC, Chesnut CH, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000; 11: 467–80PubMedCrossRef

Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004; 4(1): 50–63PubMed

Lauffenburger T, Olah AJ, Dambacher A, et al. Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic and biochemical study in patients with osteoporosis and Paget’s disease of bone. Metabolism 1977; 26: 589–605PubMedCrossRef

10.

Charles P, Poser JW, Mosekilde L, et al. Estimation of bon turnover evaluated by 47Ca-kinetics. J Clin Invest 1985; 76: 2254–8PubMedCrossRef

11.

Eriksen EF, Charles P, Meisen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127–32PubMedCrossRef

12.

Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000; 11 Suppl. 6: S18–29PubMedCrossRef

13.

Chavassieux PM, Delmas PD. Bone remodeling: biochemical markers ofbone biopsy? J Bone Miner Res 2006;21(1): 178–9PubMedCrossRef

14.

Recker RR, Lappe JM, Davies KM, et al. Reply to: bone remodeling: biochemical markers or bone biopsy? [letter]. J Bone Miner Res 2006; 21(1): 180CrossRef

15.

Halleen JM, Alatalo SL, Suominen H, et al. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15(7): 1337–45PubMedCrossRef

16.

Harris H. The human alkaline phosphatase: what we know and what we don’t know. Clin Chem Acta 1989; 186: 133–50CrossRef

17.

Stinson RA, Hamilton BA. Human liver plasma membranes contain an enzyme that removes membrane anchor from alkaline phosphatase and converts it to its plasma form. Clin Biochem 1994; 27: 49–55PubMedCrossRef

18.

Rogers A, Eastell R. Review: circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocr Metab 2005; 90(11): 6323–31PubMedCrossRef

19.

Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003; 32(1): 83–113PubMedCrossRef

20.

Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248–53PubMedCrossRef

21.

Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst 2005; 97: 59–69PubMedCrossRef

22.

Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996; 11(10): 1531–8PubMedCrossRef

23.

van Daele PLA, Seibel MJ, Hofman HA, et al. Case-control analysis of bone resorption markers, disability, and hip facture risk: the Rotterdam study. BMJ 1996; 312: 482–3PubMedCrossRef

24.

Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386–93PubMedCrossRef

25.

Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15(8): 1526–36PubMedCrossRef

26.

Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000; 11: 76–82PubMedCrossRef

27.

Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922–30PubMedCrossRef

28.

Bauer CD, Black DM, Garnero P, et al. Change in bone turnover and hip, non-vertebral and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004; 19: 1250–8PubMedCrossRef

29.

Sarkar S, Reginster J-Y, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19(3): 394–401PubMedCrossRef

30.

Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34: 344–51PubMedCrossRef

31.

Chao T-Y, Yu J-C, Ku C-H, et al. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastases in breast cancer patients. Clin Cancer Res 2005; 11: 544–50PubMed

32.

Alatalo SL, Ivaska KK, Waguespack SG, et al. Osteoclast-deried serum tartrate-resistant acid phosphatase 5b in Alber-Schoenberg disease (type II autosomal dominant osteopetrosis). Clin Chem 2004; 50: 883–90PubMedCrossRef

33.

Chen CJ, Chao TY, Chu DM, et al. Osteoblast and osteoclast activity in a malignant infantile osteopetrosis patient following bone marrow transplantation. J Pediatr Hematol Oncol 2004; 26: 5–8PubMedCrossRef

34.

Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47(4): 694–702PubMed

35.

Garnero P, Cloos P, Sornay-Rendu E, et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2002; 17: 826–33PubMedCrossRef

36.

Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and the risk of non traumatic fracture. JAMA 2004; 291: 1108–13PubMedCrossRef

37.

Hanson DA, Weis MAE, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7(11): 1251–8PubMedCrossRef

38.

Fledelius C, Johnsen AH, Cloos PAC, et al. Characterization of urinary degradation products derived from type I collagen. J Biol Chem 1997; 272(15): 9755–63PubMedCrossRef

39.

Garnero P, Fledelius C, Gineyts E, et al. Decreased β-isomerization of the C-terminal telopeptide of type I collagen α1 chain in Paget’s disease of bone. J Bone Miner Res 1997; 12(9): 1407–15PubMedCrossRef

40.

Cloos PA, Lyubimova N, Solberg H, et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 2004; 50(5-6): 279–89PubMed

41.

Cloos PAC, Fledelius C, Christgau S, et al. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int 2003; 72: 8–17PubMedCrossRef

42.

Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58(6): 618–31PubMedCrossRef

43.

Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31(1): 57–61PubMedCrossRef

44.

Gertz BJ, Clemens JD, Holland SD, et al. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 1998; 63: 102–6PubMedCrossRef

45.

Greenspan SL, Dresner-Pollak R, Parker RA, et al. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 1997; 60: 419–23PubMedCrossRef

46.

Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate. J Clin Endocrinol Metab 1994; 79: 1693–700PubMedCrossRef

47.

Hosking D. Pharmacological therapy of Paget’s and other metabolic bone diseases. Bone 2006; 38 (2 Suppl. 2): S3–7PubMedCrossRef

48.

Delmas PD, Meunier PJ. The management of Paget’s disease of bone. N Engl J Med 1997; 336: 558–66PubMedCrossRef

49.

Reid IR, Miller P, Lyles K, et al. Comparison of a single dose of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2006; 353(9): 898–908CrossRef

50.

Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646–50CrossRef

51.

Melton III LJ, Cooper C. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. New York: Academic Press, 2001: 557–77CrossRef

52.

Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000; 85(10): 3537–40PubMedCrossRef

53.

Greenspan SL, Parker RA, Ferguson L. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13(9): 1431–8PubMedCrossRef

54.

Iwamoto J, Takeda T, Sato Y, et al. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 2005; 23: 238–42CrossRef

55.

Bjarnason NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000; 26: 561–9PubMedCrossRef

56.

Delmas PD, Hardy P, Garnero P, et al. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000; 26: 553–60PubMedCrossRef

57.

Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled randomized clinical trial. J Clin Endocrinol Metab 2005; 90(5): 2762–7PubMedCrossRef

58.

Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005; 21(4): 545–53PubMedCrossRef

59.

Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12: 1–12

60.

Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103–11PubMedCrossRef

61.

Cremers SCLM, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinetics 2005; 44(6): 551–70CrossRef

62.

Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34: 890–9PubMedCrossRef

63.

Chesnut CH, Skag A, Christiansen C, et al. Effects of ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241–9CrossRef

64.

Miller P, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20(8): 1315–22PubMedCrossRef

65.

Gieschke R, Hayashi N, Vis P, et al. Modeling the effects of ibandronate on the time course of bone mineral density change in osteoporotic postmenopausal women [abstract no. P-284]. Calcif Tissue Int 2003; 72: 404

66.

Reginster J-Y, Felsenberg D, Cooper C, et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporosis Int 2006 Feb; 17(2): 159–66CrossRef

67.

Reid IR, Brown J, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–61PubMedCrossRef

68.

Abadie AC, Devogelaer J-P, Ringe JD, et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the group for the respect of ethics and excellence in science. Semin Arthritis Rheum 2005; 35(1): 1–4PubMedCrossRef

69.

Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 2001; 44(1): 202–11PubMedCrossRef

70.

Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277–85PubMedCrossRef

71.

Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in cortico-steroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801–7PubMedCrossRef

72.

Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 2003; 18(5): 919–24PubMedCrossRef

73.

Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK consensus group. QJM 1998; 91: 71–92PubMedCrossRef

74.

Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002; 60(S3A): 79–85PubMedCrossRef

75.

van Poznak C, Sauter NP. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 2005; 104(3): 443–56PubMedCrossRef

76.

van Poznack C, Sauter NP. Clinical management of osteoporosis in women with a history of breast cancer. Cancer 2005; 104(3): 443–56CrossRef

77.

Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345(13): 948–55PubMedCrossRef

78.

Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–12PubMedCrossRef

79.

Fuleihan GE, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90(6): 3209–14CrossRef

80.

Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955–62PubMed

81.

Delmas PD. How does antiresorptive therapy decrease the risk for fracture in women with osteoporosis? Bone 2000; 27: 1–3PubMedCrossRef

82.

Chesnut CH, Silverman S, Adriano K, et al. A randomized trial of nasal spray salm calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267–76PubMedCrossRef

83.

Ensrud K, Black D, Recker R, et al. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [abstract]. Bone 1998; 23 Suppl. 5: S174

84.

Adami S, Passed M, Ortolani S, et al. Effects of oral alendronate and intranasal calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383–90PubMedCrossRef

85.

Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004; 19(9): 1531–8PubMedCrossRef

86.

Marie PJ, Amman P, Boivin G, et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121–9PubMedCrossRef

87.

Marie PJ, Garba MT, Hott M, et al. Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab 1985; 11: 5–13PubMed

88.

Canalis E, Hott M, Deloffre P, et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18: 517–23PubMedCrossRef

89.

Buehler J, Chappuis P, Saffar JL, et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001; 29: 176–9PubMedCrossRef

90.

Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002; 13: 925–31PubMedCrossRef

91.

Meunier PJ, Slosman O, Delmas PD, et al. Strontium ranelate: dose dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87(5): 2060–6PubMedCrossRef

92.

Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350(5): 459–68PubMedCrossRef

93.

Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90(5): 2816–22PubMedCrossRef

94.

Rubin MR, Bilezikian JP. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005; 65(17): 2481–98PubMedCrossRef

95.

Rubin MR, Cosman F, Lindsay R, et al. The anabolic effects of parathyroid hormone. Osteoporos Int 2002; 13: 267–77PubMedCrossRef

96.

Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–41PubMedCrossRef

97.

Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among women on oestrogen with osteoporosis. Lancet 1997; 350: 550–5PubMedCrossRef

98.

Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997; 82(2): 620–8PubMedCrossRef

99.

Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen-related bone loss with human parathyroid hormone-(1-34). JAMA 1998; 280(12): 1067–73PubMedCrossRef

100.

Lane NE, Sanchez S, Genant HK, et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000; 11: 434–42PubMedCrossRef

101.

Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20(6): 962–70PubMedCrossRef

102.

Bekker PJ, Holloway DL, Rasmussen AS, et al. A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19(7): 1059–66PubMedCrossRef

103.

McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821–31PubMedCrossRef

104.

Lewiecki EM, Miller PD, McClung MR, et al. RANK ligand inhibition with denosumab (AMG 162) increases bone mineral density (BMD) in postmenopausal women after two years of treatment. Boston (MA): American College of Rheumatology, 2005: L25

105.

Roy SK, Pillai G, Woodworth TG, et al. Safety, effects on markers of bone resorption and pharmacokinetics of cathepsin-K inhibitor, AAE581, in healthy subjects [abstract no. SU447]. J Bone Miner Res 2005; 20 Suppl. 1: S293

106.

Yamada H, Ochi Y, Kawada N, et al. A potent and orally active cathepsin K inhibitor suppresses bone resorption without affecting bone formation in cynomolgus monkeys [abstract no. SU276]. J Bone Miner Res 2005; 20 Suppl. 1: S253

107.

Garnero P, Borel O, Gineyts E, et al. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 2006 Mar; 38(3): 300–9PubMedCrossRef

108.

Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10: 52–62PubMedCrossRef

109.

Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(S4): 14–27PubMedCrossRef

110.

Coleman RE. Metastatic bone disease: clinical features, pathophysiology an treatment strategies. Cancer Treat Rev 2001; 27: 165–76PubMedCrossRef

111.

Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80 Suppl. 8: 1588–94PubMedCrossRef

112.

Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29–40PubMed

113.

Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082–90PubMedCrossRef

114.

Clamp A, Danson S, Nguyen H, et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004; 5: 607–16PubMedCrossRef

115.

Clemons M, Cole DEC, Gainford MC. Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat 2006; 97(1): 81–90PubMedCrossRef

116.

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev 2002; 1: 584–93

117.

Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004; 350(16): 1655–64PubMedCrossRef

118.

Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82: 858–64PubMedCrossRef

119.

Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88 Suppl. 12: 2919–26PubMedCrossRef

120.

Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005; 2(10): 504–17PubMedCrossRef

121.

Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15(1): 32–8PubMedCrossRef

122.

Vinholes JJ, Purohit OP, Abbey ME, et al. Relationship between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243–50PubMedCrossRef

123.

Body JJ, Dumon JC, Piccart M, et al. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 1995; 10(8): 1191–6PubMedCrossRef

124.

Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91(1): 144–54PubMedCrossRef

125.

Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91(7): 1191–200PubMedCrossRef

126.

Body JJ, Diel IJ, Lichinister MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–405PubMedCrossRef

127.

Theriault RL, Lipton A, Hortobayi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846–54

128.

Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–91PubMedCrossRef

129.

Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593–602PubMed

130.

Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–82PubMedCrossRef

131.

Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613–21PubMedCrossRef

132.

Rosen LS, Gordon D, Kaminsky M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multi-center, comparative trial. Cancer 2003; 98: 1735–44PubMedCrossRef

133.

Hillner BE, Ingle JN, Chleblowski RT, et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21(21): 4042–57PubMedCrossRef

134.

Brown JE, Ellis SP, Gutcher SA. Using bone turnover markers to direct bisphosphonate therapy: is this a feasible approach? [abstract]. Cancer Treat Rev 2005; 31: S30

135.

Schlosser K, Scigalla P. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest 1997; 57 Suppl. 227: 21–8CrossRef

136.

Coleman RE, Purohit OP, Black C, et al. Double blind, randomized, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311–6PubMedCrossRef

137.

Body JJ, Diel IJ, Lichinister MR, et al. Oral ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases: results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–7PubMedCrossRef

138.

Body J-J, Lichinitser M, Tjulandin S, et al. Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial [abstract no. 534]. 41st Annual meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando. J Clin Oncol 2005; 23(16S): 12s

139.

Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of Nuclear Factorkappa B Ligand inhibitor, denosumab in patient with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12(4): 1221–8PubMedCrossRef

140.

Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005; 5(3): 419–27PubMedCrossRef

141.

Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodelling by the endothelin receptor A antagonist atrasentan. J Urol 2003; 169: 1143–9PubMedCrossRef

142.

Carducci MA, Nelson JB, Saad F, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study [abstract no. 4508]. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5–8; New Orleans. Proc Am Soc Clin Oncol 2004; 23: 383

143.

Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18(5): 589–867CrossRef

144.

Berrutti A, Gogliotti L, Tucc M, et al. Metabolic effects of single-dose cancer patients with bone metastases. Int J Biol Markers 2002; 17(4): 244–52

145.

Nenonen A, Cheng S, Ivaska KK, et al. Serum TRAP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005; 20(8): 1804–12PubMedCrossRef

Title: Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease
Potential Uses and Pitfalls
Authors: Serge Cremers
Dr Patrick Garnero
Publication date: 01-11-2006
Publisher: Springer International Publishing
Published in: Drugs / Issue 16/2006
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666160-00001

At a glance: The STEP trials

Springer Medicine

Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease

Potential Uses and Pitfalls

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 16/2006

Pilsicainide for Atrial Fibrillation

Rimonabant

Intravenous Droperidol

Treatment of Depression in Acute Coronary Syndromes with Selective Serotonin Reuptake Inhibitors

Rimonabant

Disease-Modifying Therapies in Alzheimer’s Disease